PAX Financial Group’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$484K Sell
1,851
-168
-8% -$43.1K 0.07% 122
2026
Q2
$508K Buy
2,019
+123
+6% +$26.5K 0.08% 123
2026
Q1
$412K Sell
1,896
-339
-15% -$75.2K 0.07% 134
2025
Q4
$511K Sell
2,235
-235
-10% -$53.5K 0.09% 120
2025
Q3
$572K Buy
2,470
+95
+4% +$19.3K 0.1% 126
2025
Q2
$441K Sell
2,375
-356
-13% -$66.2K 0.08% 158
2025
Q1
$572K Buy
2,731
+592
+28% +$115K 0.1% 159
2024
Q4
$380K Buy
2,139
+251
+13% +$46.1K 0.07% 191
2024
Q3
$373K Buy
1,888
+289
+18% +$53.9K 0.07% 191
2024
Q2
$274K Buy
1,599
+409
+34% +$67.8K 0.05% 210
2024
Q1
$217K Buy
+1,190
New +$205K 0.04% 216

Other funds holding ABBV

PAX Financial Group's ABBV Position: Q3 2026 in Review

PAX Financial Group reduced its AbbVie (ABBV) stake by 8.3% in Q3 2026, selling an estimated $43.1K and leaving 1,851 shares worth $484K. The position accounts for 0.07% of the portfolio, ranked #122.

PAX Financial Group first reported a position in ABBV in Q1 2024 and has held it in 11 quarters since. The position peaked at $572K in Q1 2025. 4,272 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • PAX Financial Group held 1,851 shares of AbbVie worth $484K as of Q3 2026.
  • PAX Financial Group sold 168 AbbVie shares in Q3 2026, an estimated $43.1K.
  • AbbVie made up 0.07% of PAX Financial Group's portfolio in Q3 2026, its #122 holding.
  • PAX Financial Group first reported a position in AbbVie in Q1 2024 and has held it in 11 quarters since.
  • PAX Financial Group's AbbVie position peaked at $572K in Q1 2025.
  • 4,272 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on PAX Financial Group's 13F filing for Q3 2026, filed 13 Nov 2026.